Thomann Julia, Tittel Sascha R, Voss Egbert, Oeverink Rudolf, Palm Katja, Fricke-Otto Susanne, Kapelari Klaus, Holl Reinhard W, Woelfle Joachim, Bettendorf Markus
Division of Paediatric Endocrinology and Diabetes, University Children's Hospital Heidelberg, 69120 Heidelberg, Germany.
Institute of Epidemiology and Medical Biometry, Central Institute for Biomedical Technology, Ulm University, 89081 Ulm, Germany.
Int J Neonatal Screen. 2021 Feb 12;7(1):10. doi: 10.3390/ijns7010010.
Neonatal screening for congenital primary hypothyroidism (CH) is mandatory in Germany but medical care thereafter remains inconsistent. Therefore, the registry HypoDok of the German Society of Pediatric Endocrinology and Diabetology (DGKED) was analyzed to evaluate the implementation of evidence-based guidelines and to assess the number of included patients. Inclusion criteria were (i) date of birth between 10/2001 and 05/2020 and (ii) increased thyroid-stimulating hormone (TSH) at screening and/or confirmation. The cohort was divided into before (A) and after (B) guideline publication in 02/2011, to assess the guideline's influence on medical care. A total of 659 patients were analyzed as group A ( = 327) and group B ( = 332) representing 17.5% and 10.3% of CH patients identified in the German and Austrian neonatal screening program during the respective time period. Treatment start and thyroxine doses were similar in both groups and consistent with recommendations. Regular follow-ups were documented. In the first three years of life, less than half of the patients underwent audiometry; developmental assessment was performed in 49.3% (A) and 24.8% (B) ( < 0.01). Documentation of CH patient care by pediatric endocrinologists seemed to be established, however, it reflected only a minority of the affected patients. Therefore, comprehensive documentation as an important instrument of quality assurance and evidence-based medicine should be legally enforced and officially funded in order to record, comprehend, and optimize care and outcome in patients with rare diseases such as CH.
在德国,先天性原发性甲状腺功能减退症(CH)的新生儿筛查是强制性的,但此后的医疗护理仍不一致。因此,对德国儿科内分泌与糖尿病学会(DGKED)的HypoDok登记处进行了分析,以评估循证指南的实施情况并评估纳入患者的数量。纳入标准为:(i)出生日期在2001年10月至2020年5月之间;(ii)筛查和/或确诊时促甲状腺激素(TSH)升高。该队列分为2011年2月指南发布之前(A组)和之后(B组),以评估该指南对医疗护理的影响。共分析了659例患者,A组(n = 327)和B组(n = 332)分别占各自时间段内在德国和奥地利新生儿筛查项目中确诊的CH患者的17.5%和10.3%。两组的治疗开始时间和甲状腺素剂量相似,且与建议一致。记录了定期随访情况。在生命的前三年中,不到一半的患者接受了听力测定;进行发育评估的患者比例分别为49.3%(A组)和24.8%(B组)(P < 0.01)。儿科内分泌学家对CH患者护理的记录似乎已经建立,但仅反映了少数受影响的患者。因此,作为质量保证和循证医学的重要手段,应通过法律强制实施并提供官方资金支持全面记录,以便记录、理解并优化CH等罕见病患者的护理和治疗结果。